Annual sales fell 1.0% to KRW 2.08 trillion in 2022 to KRW 2.06 trillion in 2023. Sales then rose 7.1% to KRW 2.2 trillion in 2024 and 11.2% to KRW 2.45 trillion in 2025, and 2025 was the largest year in the 2022 to 2025 period.
Operating profit moved from KRW 71.2 billion in 2022 to an operating loss of KRW 16.4 billion in 2023, which marked a turn to deficit. The operating loss narrowed to KRW 10.7 billion in 2024, and in 2025 the company returned to operating profit of KRW 36.2 billion.
The operating margin fell from 3.4% in 2022 to -0.8% in 2023 and -0.5% in 2024 before recovering to 1.5% in 2025. Net profit attributable to controlling shareholders turned positive at KRW 24 billion in 2024, but swung back to a net loss of KRW 69.5 billion in 2025.
Net loss including non-controlling interests was KRW 41.8 billion in 2025, and the gap between the two measures reflects the share held by non-controlling interests. Operating cash flow was negative at KRW -39.7 billion in 2023 and KRW -89.9 billion in 2024, then turned to KRW 24.3 billion in 2025.
On a quarterly basis, Q4 2025 was the trough, with sales of KRW 619.5 billion, an operating loss of KRW 6.73 billion and a net loss attributable to controlling shareholders of KRW 115.5 billion.
Sales bottomed at KRW 534.8 billion in Q1 2026 and then rose to KRW 596.3 billion in Q2 and KRW 702.3 billion in Q3, two consecutive quarters of growth. Q3 2026 sales were still down 4.7% from a year earlier. Operating profit rose to KRW 6.62 billion in Q2 2026 and KRW 60 billion in Q3 2026.
Press reports tied the Q3 net profit of KRW 84.3 billion partly to an upfront payment from the Curevo sale to Eli Lilly announced in May 2026, so that quarter's bottom line carries a non-recurring element. Cumulative net loss attributable to controlling shareholders over the last four quarters was KRW 47 billion.